Erman Akkus, Medical Oncology Fellow at Ankara University, shared an article by Eric V. Mastrolonardo, et al. on X:
“BMI and survival with immune checkpoint inhibitors.
- 18,434 patients
- BMI >30 vs 20-24.9
- OS with obesity
- HR: 0.69 (0.66–0.72)
except RCC.”
Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types.
Authors: Eric V. Mastrolonardo, et al.
